Risk factors for death of patients with cystic fibrosis awaiting lung transplantation
- PMID: 16387803
- PMCID: PMC2662949
- DOI: 10.1164/rccm.200410-1369OC
Risk factors for death of patients with cystic fibrosis awaiting lung transplantation
Abstract
Rationale: The optimal timing for listing of cystic fibrosis patients for lung transplantation is controversial.
Objectives: We conducted a retrospective cohort study of 343 patients listed for lung transplantation at four academic medical centers to identify risk factors for death while awaiting transplantation.
Methods: Data on possible risk factors were abstracted from medical records.
Measurements: Time to death, patient demographic characteristics, and risk factors for death while awaiting transplantation were assessed. Univariate and multivariate survival analyses were performed using Cox regression.
Results: By univariate analyses, FEV1 < or = 30% predicted (HR, 3.8; 95% CI, 2.0-7.5), Pa(CO2) > or = 50 mm Hg (HR, 1.85; 95% CI, 1.1-3.0), and shorter height (HR, 1.8; 95% CI, 1.1-3.0) were associated with a higher risk of death. Referral from an accredited cystic fibrosis center was associated with a lower risk (HR, 0.53; 95% CI, 0.30-0.92). The final multivariate model included referral from an accredited cystic fibrosis center (HR, 0.5; 95% CI, 0.3-1.0) and listing year after 1996 (HR, 0.4; 95% CI, 0.2-0.7); both were associated with a lower risk of death. FEV1 < or = 30% predicted (HR, 6.8; 95% CI, 2.4-19.3), Pa(CO2) > or = 50 mm Hg (HR, 6.9; 95% CI, 1.5-32.1), and use of a nutritional intervention (HR, 2.3; 95% CI, 1.3-4.1) were associated with increased risk. Patients with FEV1 > 30% predicted had a higher risk of death only when their Pa(CO2) was > or = 50 mm Hg (HR, 7.0; 95% CI, 1.5-32), while the increased risk of death with FEV1 < or = 30% was not further influenced by the presence of hypercapnia.
Conclusions: We identified risk factors for waiting list mortality that could impact on transplant listing and allocation guidelines.
Figures
Similar articles
-
Pulmonary Artery Pressure and Benefit of Lung Transplantation in Adult Cystic Fibrosis Patients.Ann Thorac Surg. 2016 Mar;101(3):1104-9. doi: 10.1016/j.athoracsur.2015.09.086. Epub 2015 Dec 11. Ann Thorac Surg. 2016. PMID: 26687141
-
Outcome of patients with cystic fibrosis awaiting lung transplantation.Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):819-25. doi: 10.1164/ajrccm.162.3.9910102. Am J Respir Crit Care Med. 2000. PMID: 10988089
-
Mortality Risk and Pulmonary Function in Adults With Cystic Fibrosis at Time of Wait Listing for Lung Transplantation.Ann Thorac Surg. 2015 Aug;100(2):474-9. doi: 10.1016/j.athoracsur.2015.04.022. Epub 2015 Jun 30. Ann Thorac Surg. 2015. PMID: 26138770
-
[When should we refer patients with cystic fibrosis to a lung transplantation program].Rev Med Suisse. 2008 Nov 19;4(180):2532-5. Rev Med Suisse. 2008. PMID: 19127898 Review. French.
-
Lung transplantation for cystic fibrosis.Curr Opin Organ Transplant. 2008 Oct;13(5):484-8. doi: 10.1097/MOT.0b013e32830fe6b8. Curr Opin Organ Transplant. 2008. PMID: 19060530 Review.
Cited by
-
Myeloid Zfhx3 deficiency protects against hypercapnia-induced suppression of host defense against influenza A virus.JCI Insight. 2024 Jan 16;9(4):e170316. doi: 10.1172/jci.insight.170316. JCI Insight. 2024. PMID: 38227369 Free PMC article.
-
Hypercapnia increases ACE2 expression and pseudo-SARS-CoV-2 entry in bronchial epithelial cells by augmenting cellular cholesterol.Front Immunol. 2023 Oct 12;14:1251120. doi: 10.3389/fimmu.2023.1251120. eCollection 2023. Front Immunol. 2023. PMID: 37901225 Free PMC article.
-
Lung Transplantation in a New Era in the Field of Cystic Fibrosis.Life (Basel). 2023 Jul 21;13(7):1600. doi: 10.3390/life13071600. Life (Basel). 2023. PMID: 37511977 Free PMC article. Review.
-
Resistance evolution can disrupt antibiotic exposure protection through competitive exclusion of the protective species.ISME J. 2022 Oct;16(10):2433-2447. doi: 10.1038/s41396-022-01285-w. Epub 2022 Jul 20. ISME J. 2022. PMID: 35859161 Free PMC article.
-
Development and Internal Validation of a Prognostic Model of the Probability of Death or Lung Transplantation Within 2 Years for Patients With Cystic Fibrosis and FEV1 ≤ 50% Predicted.Chest. 2022 Oct;162(4):757-767. doi: 10.1016/j.chest.2022.05.021. Epub 2022 May 26. Chest. 2022. PMID: 35643116 Free PMC article.
References
-
- Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002;21:226–232. - PubMed
-
- Zuckerman JB, Kotloff RM. Lung transplantation for cystic fibrosis [review]. Clin Chest Med 1998;19:535–554, vii. - PubMed
-
- Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187–1191. - PubMed
-
- Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999;340:1081–1091. - PubMed
-
- Geller DE, Kaplowitz H, Light MJ, Colin AA; Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Chest 1999;116:639–646. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
